TokenPost·
FDA Approves Bayer's Sunharbo to Reduce Stroke Risk After Ischemic Events
The once-daily drug reduced ischemic stroke risk by 26% in a Phase 3 trial. Major bleeding rates were similar overall, with increases in some groups.
More news
- TokenPostCanaan’s Q3 Revenue Falls 90% as Operating Loss Widens to $42.9 Million
- TokenPostGoosehead Reiterates 2026 Revenue Growth Outlook at 12% to 19%
- TokenPostWestern Europe’s Crypto Activity Rose 1.2% as Global Crypto Market Capitalization Fell
- TokenPostTrader Adds to Bet Ether Won’t Touch $1,750 by Year-End
- BeInCryptoAmericans Owe a Record $1.29 Trillion on Credit Cards. Who Pays When the Fed Hikes?
- TokenPostRay Dalio Warns Post-Election Funding Fights Could Lift Short-Term Yields